知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.042 秒)

    PHARMACEUTICAL PREPARATIONS OF A GLP-1 MOLECULE AND AN ANTI-EMETIC DRUG
    21.
    发明申请
    PHARMACEUTICAL PREPARATIONS OF A GLP-1 MOLECULE AND AN ANTI-EMETIC DRUG 审中-公开
    GLP-1分子和抗静脉药物的药物制备

    公开(公告)号：US20090305964A1

    公开(公告)日：2009-12-10

    申请号：US11912051

    申请日：2006-04-21

    申请人： Hans T. Schambye ,  Henrik Nilsson ,  Christian Hansen

    发明人： Hans T. Schambye ,  Henrik Nilsson ,  Christian Hansen

    IPC分类号： A61K38/22

    CPC分类号： A61K45/06 ,  A61K38/26 ,  A61K2300/00

    摘要： The present invention relates to a kit of parts comprising a GLP-1 molecule and an anti-emetic drug, said kit of parts being suitable for separate, sequential or/and simultaneous administration to a subject, preferably a human being. Also provided are combinations of GLP-1 or a GLP-1 analog with one or more anti-emetic drugs, as well as uses of the combinations in the manufacture of medicaments.

    摘要翻译： 本发明涉及包含GLP-1分子和抗呕吐药物的试剂盒，所述试剂盒适用于对受试者，优选人类的单独，连续或/和同时施用。 还提供了GLP-1或GLP-1类似物与一种或多种抗呕吐药物的组合，以及组合制备药物的用途。

    Method of Improving Treatments in Rheumatic and Arthritic Diseases
    22.
    发明申请
    Method of Improving Treatments in Rheumatic and Arthritic Diseases 审中-公开
    改善风湿性关节炎疾病治疗方法

    公开(公告)号：US20090035315A1

    公开(公告)日：2009-02-05

    申请号：US11629613

    申请日：2005-06-17

    申请人： Stephan Christgau ,  Christian Hansen ,  Henrik Nilsson

    发明人： Stephan Christgau ,  Christian Hansen ,  Henrik Nilsson

    IPC分类号： A61K39/395 ,  A61K31/662 ,  A61K31/351 ,  A61K31/715 ,  A61K31/724 ,  A61K31/192 ,  A61K31/18 ,  A61K31/167 ,  A61K31/60 ,  A61K31/235 ,  A61K31/5415 ,  A61K31/56 ,  A61K38/00 ,  A61K31/415

    CPC分类号： A61K31/519 ,  A61K31/28 ,  A61K31/403 ,  A61K31/573 ,  A61K31/65 ,  A61K31/663 ,  A61K31/7008 ,  A61K31/737 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

    摘要： Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and/or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors/antagonists of IL-1, inhibitors/antagonists of TNF-alpha, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors/antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulphate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compositions comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance as defined above.

    摘要翻译： 改善关节疾病的治疗，例如， 骨关节炎和类风湿性关节炎以及疼痛，其中单独施用含锶化合物或与一种或多种第二治疗和/或预防活性物质组合施用，所述第二治疗和/或预防活性物质选自二膦酸盐，葡糖胺，扑灭剂，止痛剂，疾病 修饰抗风湿化合物（DMARD），选择性雌激素受体调节剂（SERM），芳香酶抑制剂，非甾体抗炎药（NSAID），COX-2抑制剂，COX-3抑制剂，阿片样物质，IL-1抑制剂/拮抗剂 ，TNF-α的抑制剂/拮抗剂，基质金属蛋白酶（MMPs）的抑制剂，组织蛋白酶K抑制剂，RANK-配体的抑制剂/拮抗剂，他汀类，糖皮质激素，硫酸软骨素，NMDA受体拮抗剂，白细胞介素-I转化酶抑制剂， 降钙素基因相关肽拮抗剂，甘氨酸拮抗剂，香草素受体拮抗剂，诱导型一氧化氮合成酶抑制剂（iNOS），N-乙酰 胆碱受体激动剂，神经激肽拮抗剂，精神抑制剂，PAR2受体拮抗剂和作用于关节组织成分的合成代谢生长因子。 包含含锶化合物和如上定义的第二治疗和/或预防活性物质的药物组合物。

    Composition Comprising Pyy for the Treatment of Gastrointestinal Disorders
    24.
    发明申请
    Composition Comprising Pyy for the Treatment of Gastrointestinal Disorders 审中-公开
    包括Pyy治疗胃肠道疾病的组成

    公开(公告)号：US20080125360A1

    公开(公告)日：2008-05-29

    申请号：US11596973

    申请日：2005-05-18

    申请人： Henrik Nilsson

    发明人： Henrik Nilsson

    IPC分类号： A61K38/22 ,  A61K31/137 ,  A61K31/55 ,  A61P1/00 ,  A61P1/14

    CPC分类号： A61K31/55 ,  A61K31/137 ,  A61K38/22 ,  A61K2300/00

    摘要： The present invention relates to PYY or functional equivalents thereof for use in pharmaceutical compositions. The pharmaceutical compositions are in particular useful in the treatment of functional gastrointestinal disorders, such as irritable bowel disease and functional dyspepsia. The invention further relates to methods of treatment using said compositions. Further included is the combination of PYY or functional equivalents thereof with a secondary active ingredient such as an anti-emetic drug.

    摘要翻译： 本发明涉及用于药物组合物的PYY或其功能等同物。 药物组合物特别可用于治疗功能性胃肠道疾病，例如肠易激综合征和功能性消化不良。 本发明还涉及使用所述组合物的治疗方法。 还包括PYY或其功能等同物与次级活性成分如抗呕吐药物的组合。

    Method for Improving the Medical Treatment of Pain
    27.
    发明申请
    Method for Improving the Medical Treatment of Pain 审中-公开
    改善疼痛治疗方法

    公开(公告)号：US20080317849A1

    公开(公告)日：2008-12-25

    申请号：US11629612

    申请日：2005-06-17

    申请人： Stephan Christgau ,  Christian Hansen ,  Henrik Nilsson

    发明人： Stephan Christgau ,  Christian Hansen ,  Henrik Nilsson

    IPC分类号： A61K31/192 ,  A61K31/185 ,  A61K31/415 ,  A61K9/20 ,  A61P25/00 ,  A61P19/02 ,  A61K31/60

    CPC分类号： A61K31/192 ,  A61K31/415 ,  A61K33/24 ,  A61K2300/00

    摘要： Methods for improving pain management in a mammal, the methods comprising administering a combination of a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents to the mammal. Pharmaceutical compositions for use in such methods, comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents.

    摘要翻译： 用于改善哺乳动物疼痛管理的方法，所述方法包括向哺乳动物施用含锶化合物和选自镇痛剂，抗炎剂和姑息治疗剂的第二治疗和/或预防活性物质的组合物 。 用于这种方法的药物组合物，其包含含锶化合物和选自止痛剂，抗炎剂和姑息治疗剂的第二治疗和/或预防活性物质。

    Use Of Secretagogue For The Teatment Of Ghrelin Deficiency
    30.
    发明申请
    Use Of Secretagogue For The Teatment Of Ghrelin Deficiency 审中-公开
    使用秘书处的Ghrelin缺乏症

    公开(公告)号：US20080171700A1

    公开(公告)日：2008-07-17

    申请号：US11578135

    申请日：2005-04-07

    申请人： Henrik Nilsson ,  Birgitte Holst Lange ,  Claes Post ,  Tina Geritz Nielsen

    发明人： Henrik Nilsson ,  Birgitte Holst Lange ,  Claes Post ,  Tina Geritz Nielsen

    IPC分类号： A61K38/25 ,  A61P5/00 ,  A61P3/00 ,  A61P3/04

    CPC分类号： A61K38/25

    摘要： The present invention relates to the use of a growth hormone (GH) secretagogue, such as a ghrelin-like compound, for the preparation of a medicament for the prophylaxis or treatment of ghrelin deficiency, and/or undesirable symptoms associated therewith, in an individual at risk of acquiring partial or complete ghrelin deficiency resulting from a medical treatment and/or from a pathological condition. The present invention also relates to use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of one or more of: loss of fat mass, loss of lean body mass, weight loss, cachexia, loss of appetite, immunological dysfunction, malnutrition, disrupted sleep pattern, sleepiness, reduction in intestinal absorption and/or intestinal mobility problems in an individual suffering from, or at risk of suffering from, ghrelin deficiency. Furthermore, the present invention relates to the use of a secretagogue, such as a ghrelin-like compound, for the production of a medicament for preventing weight increase in an individual either: a) being converted from a hyperthyroidic state to euthyroid state, or b) in remission from being converted from a hyperthyroidic state to euthyroid state.

    摘要翻译： 本发明涉及生长激素（GH）促分泌素如生长素释放肽样化合物在个体中用于预防或治疗生长素释放肽缺乏症和/或与之相关的不良症状的药物的用途 有获得由医疗和/或病理状况引起的部分或完全的生长素释放肽缺乏的风险。 本发明还涉及促分泌素化合物在制备用于预防或治疗以下中的一种或多种的药物中的用途：脂肪量的损失，瘦体重的减少，体重减轻，恶病质，食欲不振，免疫功能障碍 ，营养不良，睡眠模式紊乱，困倦，减少肠道吸收和/或肠道运动问题，或者有遭受生长素释放肽缺乏症的个体。 此外，本发明涉及促分泌素如生长素释放肽样化合物在制备用于预防个体体重增加的药物中的用途：a）从甲状腺功能亢进状态转变为甲状腺功能状态，或b ）缓解从甲状腺功能亢进状态转变为甲状腺功能状态。